2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
复制标题
DOI：
10.1161/cir.0b013e3182742c84
复制
发表时间：
2013-01-29
期刊：
影响因子：
37.8
通讯作者：
Zhao, David X.
中科院分区：
文献类型：
--
作者：
O'Gara, Patrick T.;Kushner, Frederick G.;Zhao, David X.
1.1. 本文件中列出的建议尽可能以证据为基础。目前的文件是一个完整的修订，包括在2010年11月之前进行的广泛证据审查，并在2012年8月之前增加了额外的精选参考文献。检索仅限于在人类受试者中进行的研究以及与人类受试者有关的评论和其他证据；全部以英文出版。关键搜索词包括但不限于：急性冠状动脉综合征、经皮冠状动脉介入治疗、冠状动脉搭桥、心肌梗死、st段抬高型心肌梗死、冠状动脉支架、血运重建术、抗凝治疗、抗血小板治疗、抗血栓治疗、糖蛋白IIb/IIIa抑制剂治疗、药物治疗、质子泵抑制剂、植入式心律转复除颤器治疗、心源性休克、纤溶治疗、溶栓治疗、硝酸盐、机械性并发症、心律失常、心绞痛、慢性稳定型心绞痛、糖尿病、慢性肾病、死亡率、发病率、老年、伦理、对比肾病。额外的搜索将这些主题与以下子主题交叉引用：经皮冠状动脉介入治疗、冠状动脉搭桥术、心脏康复和二级预防。此外，委员会审查了ACCF和AHA先前发表的与主题有关的文件。本文档中选择和发布的参考文献具有代表性，但不包括所有内容。本指南的重点是STEMI患者的管理。对2004年STEMI指南的更新于2007年和2009年发布（5-7）。特别强调再灌注治疗的进展，区域护理系统的组织，转移算法，循证抗血栓和医学治疗，以及二级预防策略，以优化以患者为中心的护理。通过设计，该文件的范围比2004年STEMI指南更窄，试图为从业者提供更集中的工具。适当时提供了与管理指南相关的参考资料，包括经皮冠状动脉介入治疗（PCI）、冠状动脉旁路移植术（CABG）、心力衰竭（HF）、心脏装置和二级预防相关的参考资料。
1.1. Methodology and Evidence Review The recommendations listed in this document are, whenever possible, evidence based. The current document constitutes a full revision and includes an extensive evidence review which was conducted through November 2010, with additional selected references added through August 2012. Searches were limited to studies conducted in human subjects and reviews and other evidence pertaining to human subjects; all were published in English. Key search words included but were not limited to: acute coronary syndromes, percutaneous coronary intervention, coronary artery bypass graft, myocardial infarction, ST-elevation myocardial infarction, coronary stent, revascularization, anticoagulant therapy, antiplatelet therapy, antithrombotic therapy, glycoprotein IIb/IIIa inhibitor therapy, pharmacotherapy, proton-pump inhibitor, implantable cardioverter-defibrillator therapy, cardiogenic shock, fibrinolytic therapy, thrombolytic therapy, nitrates, mechanical complications, arrhythmia, angina, chronic stable angina, diabetes, chronic kidney disease, mortality, morbidity, elderly, ethics, and contrast nephropathy. Additional searches cross-referenced these topics with the following subtopics: percutaneous coronary intervention, coronary artery bypass graft, cardiac rehabilitation, and secondary prevention. Additionally, the committee reviewed documents related to the subject matter previously published by the ACCF and AHA. References selected and published in this document are representative and not all inclusive. The focus of this guideline is the management of patients with STEMI. Updates to the 2004 STEMI guideline were published in 2007 and 2009 (5–7). Particular emphasis is placed on advances in reperfusion therapy, organization of regional systems of care, transfer algorithms, evidence-based antithrombotic and medical therapies, and secondary prevention strategies to optimize patient-centered care. By design, the document is narrower in scope than the 2004 STEMI Guideline, in an attempt to provide a more focused tool for practitioners. References related to management guidelines are provided whenever appropriate, including those pertaining to percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG), heart failure (HF), cardiac devices, and secondary prevention.